Presentations include analytical validation of Myriad’s high-definition tumor informed MRD assay for breast cancer and its Breast Cancer Risk Assessment Tool MyRisk® with RiskScore® […]
Canary Speech recognized for achievements in non-invasive diagnostics in the most promising private digital health companies across the globe. […]
First program to result from end-to-end use of OS to identify a novel target and new chemical matter, which moved from target ID to IND enabling studies in under 18 months with ~200 compounds synthesized […]
Embolic device designed for improved preparation, delivery, and deep vessel filling for treating tumors and other interventional oncology uses. […]
EDWARDS’ SAPIEN 3 ULTRA RESILIA VALVE DEMONSTRATES CONTINUED EXCELLENT OUTCOMES FOR PATIENTS IN REAL WORLD DATA […]
WRAPSODY achieves 82% target lesion primary patency at six months in the single-arm cohort of the US pivotal trial […]
Myriad Genetics Announces Prequel® Prenatal Screening Can Now be Performed Eight Weeks into Pregnancy […]
Agreement will expand worldwide access and better position Myriad’s GIS as a potential companion diagnostic across multiple potential tumor types […]
Four Integration Methods Aim to Combat Healthcare-Associated Infections & Improve Device Performance […]
SINTX TECHNOLOGIES AND NED MEDICAL PARTNER TO ADVANCE CUTTING-EDGE CERAMIC MICROSPHERE MEDICAL DEVICES FOR CANCER TREATMENT […]
First of Its Kind HPV Self-Collection Study Launched to Improve Cervical Cancer Screening in Underserved Communities […]
Seek Labs Announces Partnership with Cerbrec […]